Status:
UNKNOWN
The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions
Lead Sponsor:
Sun Yat-sen University
Conditions:
Hypothyroidism
Exophthalmos
Eligibility:
All Genders
8-90 years
Phase:
PHASE3
Brief Summary
Iodine 131 (131I） treatment on Graves disease and Graves ophthalmopathy relationship has always been the focus of debate. Majority view is that the current treatment does not increase 131I Graves opht...
Detailed Description
no more description
Eligibility Criteria
Inclusion
- a typical clinical symptoms of Graves disease, diffuse goiter, eye signs (including exophthalmos), thyroid function (FT3, FT4, rTSH) and thyroid autoantibodies and imaging examinations to confirmed.
Exclusion
- 131I treatment contraindications, those who have not signed the informed consent, failure to complete treatment and follow-up estimates of patients and patients not suitable for radionuclide therapy
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
627 Patients enrolled
Trial Details
Trial ID
NCT01204359
Start Date
July 1 2007
End Date
December 1 2016
Last Update
May 25 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China, 510120
2
Ningyi Jiang
Guangzhou, China